

Prescribing information and adverse event reporting can be found at the bottom of this page.



Helping your eligible patients prescribed FABHALTA® (iptacopan) start and stay on track with their treatment

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370.

FABHALTA® is indicated as a monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. This material has been developed and funded by Novartis Pharmaceuticals UK Ltd. and is intended for use by UK healthcare professionals only.

Connected – Stronger Together is a patient support programme developed and funded by Novartis Pharmaceuticals UK Ltd. and is offered in partnership with IQVIA IES Ltd. It is a service for patients who have been prescribed FABHALTA® (iptacopan) for their PNH treatment.



Scan or click (if viewing digitally) the QR code to view the Prescribing Information.

Need for patient support

The lack of awareness, education, and understanding of a rare disease like PNH may contribute to patients' feelings of isolation and hopelessness.¹⁻³ Patients who do not understand their condition and recognise that it requires treatment could be less motivated to be adherent to treatment. According to a 2023 systemic review and meta-analysis including 1,559 patients with rare disease, **adherence averaged only between 28% and 53%.**⁴



Social support has been shown to impact patients' understanding, beliefs, and attitudes about their condition, as well as influence treatment.⁵



Nurse-led digital health interventions and telephone support for chronic disease have been shown to significantly improve medication adherence and quality of life.^{5,6}



Patients find value in programmes that help them manage the administrative (i.e., 'paperwork') and logistical barriers that can impede medication access and adherence (i.e., reminder assistance tools, managing adherence while travelling, and adherence routine development).⁷

Supporting eligible PNH patients on their treatment journey

Connected – Stronger Together provides support to patients prescribed iptacopan to help them better understand and manage their PNH and treatment. Iptacopan is the first oral monotherapy to be approved for the treatment of adult patients with PNH who have haemolytic anaemia.⁸

With the Connected – Stronger Together patient support programme, patients can:


- Receive personalised support based on their specific challenges
- Understand and help to manage possible side effects associated with iptacopan
- Learn more about their treatment with iptacopan
- Access information about treatment tracking and monitoring
- Learn more about PNH
- Find information and sources of emotional and wellbeing support

Provide your eligible patients prescribed iptacopan with the knowledge and confidence to manage their condition, with hopes of improving medication adherence, by encouraging them to sign up to **Connected – Stronger Together**.


Support programme offerings and communication channels

Studies have shown that the benefits of patient support programmes increase when more than one type of intervention is offered.⁷


Connected – Stronger Together provides information on PNH and treatment with iptacopan through various channels of support:




Starter kit
A detailed brochure that provides patients and their caregivers with information on PNH and treatment with iptacopan, along with a treatment guide, therapy diary, goal setting planner, appointment planner, contact card, and stickers for reminding patients to take their medication.




Nurse support
Inbound and outbound nurse calls for informational, logistical, and emotional support.
One-on-one personalised support from trained nurses can help patients be more comfortable and adherent with their treatment and disease management.⁵⁻⁷



Educational resources
Digital and print resources about PNH and iptacopan for tracking medication, symptoms, and mood over time, and for connecting with support networks. Online resources are available to patients at www.pro.novartis.com/uk-en/public/medicines/haematology/fabhalta/psp. Digital learning tools may improve patient knowledge, self-care behaviours, emotional state, satisfaction with care, and confidence towards treatment.⁹



Emails
Important topics related to PNH and treatment with iptacopan, including its mechanism of action, dosing, tips for establishing a medication routine, and side-effects management, plus links to additional information and resources on a website.
Emails with educational information support patients during treatment, and links to download additional resources can improve medication adherence.^{10,11}



SMS text messages

- Daily medication reminders help patients remain adherent with their medicines each day
- Motivational texts help patients stay engaged while managing their disease and treatment

In studies, medical compliance reminders were found to improve medication regimen adherence when using an SMS-reminder intervention.¹⁰

Two simple ways for your patients to enrol:

Help your patients prescribed iptacopan stay informed and adherent with their treatment by enrolling them in **Connected – Stronger Together.**

Online



Scan this QR code or visit:
www.fabhalta-cst.co.uk

Phone 01794 331 148

References

1. Bektas M, Copley-Merriman C, Khan S, Sarda, SP, Shammo, J. M. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. *Journal of Managed Care & Specialty Pharmacy*. 2020;26(suppl 12-b):8S-14S.
2. Desai D, Hadker N, Francis A, *et al*. Health-related quality of life reported among patients with paroxysmal nocturnal hemoglobinuria: impact of treatment with pegcetacoplan and C5-inhibitors. *Blood*. 2022;140(suppl 1):11445-11446.
3. Panse J, Sicre De Fontbrune F, Burmester P, *et al*. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: patient-reported insights on symptoms and quality of life. *European Journal of Haematology*. 2022;109(4):351-363.
4. Garcia-Munoz AM, Victori-Montersinos D, Cerda B, Ballester P, de Velasco EL, Zafrilla P. Self-reported medication adherence measured with Morisky Scales in rare disease patients: a systematic review and meta-analysis. *Healthcare*. 2023;11:1609.
5. Lee A, Wong A, Hung T, Yan J, Yang S. Nurse-led telehealth intervention for rehabilitation (telerehabilitation) among community-dwelling patients with chronic diseases: systematic review and meta-analysis. *J Med Internet Res*. 2022;24(11):e40364.
6. Kes D, Polat U. The effect of nurse-led telephone support on adherence to blood pressure control and drug treatment in individuals with primary hypertension: a randomized controlled study. *Int J Nurs Pract*. 2022 Jun;28(3):e12995.
7. Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. *Patient Preference and Adherence*. 2016;10:711-725.
8. FABHALTA® (iptacopan) Summary of Product Characteristics.
9. Win KT, Hassan NM, Bonney A, Iverson D. Benefits of online health education: perceptions from consumers and health professionals. *J Med Syst*. 2015 Mar;39(3):27.
10. Schwebel FJ, Larimer, ME. Using text message reminders in health care services: a narrative literature review. *Internet Interventions*. 2018;13:82-104.
11. Aremu TO, Oluwole OE, Adeyinka KO, Schommer JC. Medication Adherence and Compliance: Recipe for Improving Patient Outcomes. *Pharmacy (Basel)*. 2022 Aug;10(5):106.

Prescribing Information

Scan or click (if viewing digitally)
the QR code to view the
Prescribing Information.

